Hospital Universitario Príncipe de Asturias -ko ikertzaileekin lankidetzan egindako argitalpenak (51)

2024

  1. COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant

    Cancers, Vol. 16, Núm. 2

  2. Comprehensive evaluation of genetic and acquired thrombophilia markers for an individualized prediction of clinical thrombosis in patients with lymphoma and multiple myeloma

    Journal of Thrombosis and Thrombolysis, Vol. 57, Núm. 6, pp. 984-995

  3. Impact of early palliative care intervention in autologous bone marrow transplantation: feasibility of a multicentric study

    BMC Palliative Care, Vol. 23, Núm. 1

  4. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

    Haematologica, Vol. 109, Núm. 1, pp. 115-128

  5. SARS-CoV-2-Specific T Lymphocytes Analysis in mRNA-Vaccinated Patients with B-Cell Lymphoid Malignancies on Active Treatment

    Vaccines, Vol. 12, Núm. 9

2023

  1. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

    Cancers, Vol. 15, Núm. 5

2021

  1. Risk factors and mortality of COVID-19 in patients with lymphoma: A multicenter study

    HemaSphere, Vol. 5, Núm. 3, pp. 1-8

  2. Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study

    Cancer Medicine, Vol. 10, Núm. 21, pp. 7629-7640

2020

  1. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study

    Journal of Hematology and Oncology, Vol. 13, Núm. 1

  2. Impacto de la Covid-19 en pacientes adultos con neoplasias hematológicas: informe del registro Covid-19 de la asociación madrileña de hematología y hemoterapia (AMHH)

    Anales de la Real Academia Nacional de Medicina, Núm. 137, pp. 202-208

  3. Jumping Translocation in a Patient with Acute Leukemia and Fatal Evolution

    Case Reports in Oncology, Vol. 13, Núm. 2, pp. 1026-1030

  4. Micafungin as antifungal prophylaxis in non-transplanted haemotological patients

    Revista Espanola de Quimioterapia, Vol. 33, Núm. 1, pp. 44-48

2019

  1. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance

    Haematologica, Vol. 104, Núm. 11, pp. 2249-2257

2016

  1. A team-based multidisciplinary approach to managing peripherally inserted central catheter complications in high-risk haematological patients: a prospective study

    Supportive Care in Cancer, Vol. 24, Núm. 1, pp. 93-101

  2. Epidemiología de la leucemia mieloide crónica en España y sus posibles implicaciones terapéuticas

    Revista Clinica Espanola

  3. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

    Leukemia Research, Vol. 40, pp. 1-9

2015

  1. Atypical IgM multiple myeloma with deletion of c-MAF

    International Journal of Laboratory Hematology, Vol. 37, Núm. 5, pp. 686-689

2014

  1. Review of risk factors, diagnosis criteria and treatment in multiple myeloma

    Multiple Myeloma: Risk Factors, Diagnosis and Treatments (Nova Science Publishers, Inc.), pp. 101-110

2013

  1. Actualización en linfomas primarios de mama: Serie de casos y revisión de la literatura

    Progresos de Obstetricia y Ginecologia

  2. Post-bone-marrow-transplant leukemia cutis

    Dermatology Online Journal, Vol. 19, Núm. 2